Ticker >

Gennex Lab share price

Gennex Laboratories Ltd.

BSE: 531739 SECTOR: Pharmaceuticals & Drugs  47k   218   19

16.94
0 0
BSE: 17 May 04:01 PM

Price Summary

Today's High

₹ 17.84

Today's Low

₹ 16.75

52 Week High

₹ 21.89

52 Week Low

₹ 6.12

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

385.3 Cr.

Enterprise Value

373.11 Cr.

No. of Shares

22.74 Cr.

P/E

40.38

P/B

2.4

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  7.07

CASH

14.45 Cr.

DEBT

2.27 Cr.

Promoter Holding

18.42 %

EPS (TTM)

₹  0.42

Sales Growth

6.35%

ROE

7.43 %

ROCE

10.7%

Profit Growth

16.2 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.35%
3 Year5.39%
5 Year8.26%

Profit Growth

1 Year16.2%
3 Year34.92%
5 Year40.4%

ROE%

1 Year7.43%
3 Year9.15%
5 Year7.9%

ROCE %

1 Year10.7%
3 Year11.89%
5 Year10.89%

Debt/Equity

0.0287

Price to Cash Flow

-26.66

Interest Cover Ratio

5.88351117128678

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 18.42 0
Dec 2023 23.6 0
Sep 2023 23.6 34.14
Jun 2023 23.38 34.17
Mar 2023 23.38 3.46
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 34.9180601413267% for the Past 3 years.
  • The company has significantly decreased its debt by 7.8540483 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 44.5093247006609 days.
  • Company has a healthy liquidity position with current ratio of 4.53471342085295.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.96618620398575.

 Limitations

  • The company has shown a poor revenue growth of 5.38674278834299% for the Past 3 years.
  • Company has negative cash flow from operations of -14.4505867.
  • Promoter stake has been decreased from 23.6% to 18.42%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 14.62 18.15 14.15 14.3 19.32
Total Expenditure 12.8 16.88 10.23 10.27 15.64
Operating Profit 1.82 1.27 3.92 4.03 3.68
Other Income 0 1.59 0.03 0 0
Interest 0.18 0.51 0.3 0.28 0.32
Depreciation 0.19 0.2 0.2 0.2 0.2
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.45 2.16 3.45 3.55 3.16
Tax 0.37 0.48 0.87 0.89 0.52
Profit After Tax 1.08 1.67 2.57 2.66 2.64
Adjusted EPS (Rs) 0.07 0.09 0.15 0.15 0.15

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 55.8 55.62 59.65 61.21 65.1
Total Expenditure 51.78 52.37 53.12 55.84 60.52
Operating Profit 4.02 3.25 6.53 5.38 4.58
Other Income 0.78 0.95 0.52 1.38 3.4
Interest 0.79 0.75 0.74 0.88 1.23
Depreciation 0.98 1 0.88 0.79 0.74
Exceptional Items 0 0.11 -0.37 0 0
Profit Before Tax 3.03 2.55 5.06 5.09 6.01
Tax 0.81 0.69 1.02 1.17 1.45
Net Profit 2.22 1.86 4.04 3.92 4.56
Adjusted EPS (Rs.) 0.17 0.14 0.3 0.3 0.26

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 12.65 12.65 12.65 12.65 18.02
Total Reserves 21.35 23.2 27.24 31.35 61
Borrowings 0 0 0 0 1.29
Other N/C liabilities 0.62 0.41 0.17 0 -0.14
Current liabilities 17.3 20.86 19.02 24.21 15.91
Total Liabilities 51.91 57.13 59.08 68.21 96.08
Assets
Net Block 15.64 14.93 14.13 13.7 15.18
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 7.01 7.01 7.01 7.01 8.26
Loans & Advances 0.22 0.22 1.57 0.32 0.48
Other N/C Assets 0 0 0 0 0
Current Assets 29.04 34.97 36.38 47.18 72.16
Total Assets 51.91 57.13 59.08 68.21 96.08
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 3.03 2.55 5.06 5.28 6.01
Adjustment 1.73 1.68 1.57 2.57 -0.74
Changes in Assets & Liabilities -2.53 -5.9 -6.54 -0.1 -19.73
Tax Paid -0.35 0 -1.53 -1.11 0
Operating Cash Flow 1.88 -1.67 -1.44 6.64 -14.45
Investing Cash Flow -0.99 -0.22 -0.02 -1.26 -0.77
Financing Cash Flow 1.25 -0.35 1.62 1.87 21.35
Net Cash Flow 2.13 -2.23 0.16 7.24 6.14

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 23.38 23.38 23.60 23.60 18.42
india securities brooking... 0.03 0.03 0.03 0.03 0.03
premier fiscal services p... 20.95 20.95 21.15 21.15 16.50
prudential investment lim... 0.02 0.02 0.02 0.02 0.02
subhash chand bhura trust... 0.43 0.43 0.43 0.43 0.34
vab ventures limited 1.92 1.92 1.93 1.93 1.51
vinod baid 0.03 0.03 0.03 0.03 0.02
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 76.62 76.62 76.40 76.40 81.58
brij bhushan agarwal - - - - 1.98
hemant kumar jain - - - - 1.76
jms mines & minerals priv... - - - - 3.47
llp 0.04 0.03 - 0.13 0.38
maryada barter pvt. ltd. - 3.05 3.07 3.19 2.26
rajababu sampatrao bandel... 1.91 1.91 1.93 1.93 1.51
sanjay kumar 2.08 2.08 2.10 2.10 1.64
sumita talwar 2.37 2.37 2.39 2.39 1.86
sumitra devi agarwal - - - - 1.98
vidya tradecon private li... - - - - 2.20
icm finance pvt ltd - 2.51 3.66 3.66 -
kamal kumar dugar 3.66 3.83 3.30 1.99 -
ridhi sidhi distributor (... - - - 2.53 -
sunil talwar 2.52 2.52 2.54 2.54 -
adhunik dealcom private l... - 2.50 2.52 - -
jms mining private limite... - 5.03 5.07 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Gennex Laboratories informs about newspaper publication16 Feb 2024, 5:29PM Gennex Lab - Quaterly Results14 Feb 2024, 5:27PM Gennex Lab - Quaterly Results14 Feb 2024, 5:27PM Gennex Laboratories informs about updates13 Dec 2023, 3:03PM Gennex Lab - Quaterly Results14 Nov 2023, 12:00PM Gennex Lab - Quaterly Results14 Nov 2023, 12:00PM Gennex Laboratories gets WHO-GMP Certificate from Government of Telangana11 Jul 2023, 2:45PM Gennex Laboratories informs about closure of trading window1 Jul 2023, 4:00PM Gennex Laboratories informs about outcome of board meeting 31 May 2023, 10:36AM Gennex Laboratories informs about acquisition2 Mar 2023, 4:56PM Gennex Laboratories informs about disclosure 23 Nov 2022, 10:57AM Gennex Laboratories informs about board meeting 19 Sep 2022, 5:10PM Gennex Laboratories informs about disclosure16 Sep 2022, 3:35PM Gennex Laboratories informs about disclosure16 Sep 2022, 12:01PM Gennex Laboratories informs about allotment of equity shares26 Aug 2022, 4:22PM Gennex Laboratories informs about disclosure 11 Aug 2022, 4:50PM Gennex Laboratories informs about disclosure 26 Jul 2022, 4:50PM Gennex Laboratories informs about disclosures 26 Jul 2022, 4:23PM Gennex Laboratories informs about trading window closure1 Jul 2022, 5:05PM Gennex Laboratories informs about trading window closure6 Apr 2022, 2:18PM Gennex Laboratories to raise funds through permissible modes29 Mar 2022, 11:22AM Gennex Lab - Quaterly Results14 Feb 2022, 5:41PM Gennex Laboratories submits certificate12 Jan 2022, 5:14PM Gennex Laboratories to make Deccan Remedies as subsidiary 5 Jan 2022, 2:29PM Gennex Laboratories informs about compliance certificate30 Apr 2021, 1:28PM Gennex Laboratories informs about board meeting3 Feb 2021, 4:29PM Gennex Laboratories informs about appointment of non-executive director21 Dec 2020, 1:34PM Gennex Laboratories informs about board meeting 18 Dec 2020, 5:04PM Gennex Laboratories informs about related party transaction3 Dec 2020, 1:46PM Gennex Laboratories informs about compliance certificate19 Oct 2020, 1:43PM Gennex Laboratories informs about outcome of board meeting14 Aug 2020, 4:51PM Gennex Laboratories gets WHO-GMP Certificate from Drug Control Administration4 Jun 2020, 10:13AM

Gennex Lab Stock Price Analysis and Quick Research Report. Is Gennex Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Gennex Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Gennex Lab cash from the operating activity was Rs -14.4505867 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Gennex Lab has a Debt to Equity ratio of 0.0287 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Gennex Lab , the EPS growth was -12.7450980392157 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Gennex Lab has OPM of 7.04012733586688 % which is a bad sign for profitability.
     
  • ROE: Gennex Lab have a poor ROE of 7.43337458517326 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Gennex Lab is Rs 16.94. One can use valuation calculators of ticker to know if Gennex Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Gennex Lab
X